Business Context and Reporting Period
This Form 8-K Current Report was filed by Boston Scientific Corporation on February 18, 2026. The filing primarily addresses corporate governance changes, specifically the expansion of the Board of Directors, and a significant increase in the company's stock repurchase authorization.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation and the stock repurchase program:
- Stock Repurchase Authorization: Increased by $4.0 billion, bringing the total authorized amount to $5.0 billion.
- Director Compensation (Prorated): New directors Catherine R. Smith and Christophe P. Weber are eligible for a cash retainer of approximately $24,663 and an equity award valued at approximately $42,420 each.
Material Changes
The following material changes were reported effective February 18, 2026:
- Board Expansion: The Board of Directors increased its size from ten to twelve members.
- New Appointments: Catherine R. Smith and Christophe P. Weber were appointed as directors. Ms. Smith was assigned to the Audit and Nominating and Governance Committees, while Mr. Weber was assigned to the Executive Compensation and Human Resources and Risk, Science and Technology Committees.
- Capital Allocation: The Board approved an additional $4.0 billion for common stock repurchases, increasing the total program size to $5.0 billion. The filing states that the entire $5.0 billion remains available as of the report date.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, operational outlook, or management commentary on future performance. No new risks or contingencies were disclosed in this report. The document notes that indemnification agreements will be entered into with the new directors in the standard form used for existing directors.
Investor Verification Checklist
- Verify the total remaining balance of the $5.0 billion stock repurchase program in subsequent quarterly reports.
- Confirm the exact number of shares granted to the new directors on the grant date of March 2, 2026.
- Review the full text of the press release (Exhibit 99.1) for any additional context regarding the strategic rationale for the board expansion.
- Monitor future filings for the actual execution of the stock repurchase program.